Cantor Fitzgerald Reiterates Overweight on KalVista Pharma
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on KalVista Pharma (NASDAQ:KALV).
September 09, 2024 | 5:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on KalVista Pharma, indicating a positive outlook on the stock.
The reiteration of an Overweight rating by a reputable analyst suggests confidence in KalVista Pharma's future performance, likely leading to positive investor sentiment and potential stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100